Paper - WANFANG MED ONLINE

You Position: Home > Paper

特发性肺纤维化风险预测模型的进展

( views:207, downloads:472 )

Author:: No author available

Journal Title:: Chinese Journal of Tuberculosis and Respiratory Diseases

Issue:: 10

DOI:: 10.3760/cma.j.issn.1001-0939.2018.10.014

Key Word:: No keyword available

Abstract：特发性肺纤维化(idiopathic pulmonary fibrosis,IPF)是临床上具有代表性的一种慢性纤维化性肺疾病,病变局限在肺脏,好发于中老年男性,临床表现为进行性加重的呼吸困难、限制性通气障碍伴弥散量降低,胸部高分辨率CT(HRCT)和(或)组织病理表现为普通型间质性肺炎(usually interstitial pneumonia,UIP)型.IPF起病隐匿,病因不明,可能的危险因素包括吸烟、职业环境暴露、感染、胃食管反流、增龄和遗传因素,中位生存期为3～5年1-3].近年的研究探索IPF的风险预测模型,对疾病的严重程度进行分级,预测死亡风险,便于临床选择合适的治疗,针对不同疾病阶段的患者开展临床研究.现将对IPF风险预测模型的研究进展综述如下.

Reference

[1]YE Qiao,HUANG Kewu,DING Yi,etc.Cigarette smoking contributes to idiopathic pulmonary fibrosis associated with emphysema[J].2014,(3).
[2]WEI Yan,Li-Ying Peng,Cheng-Jun Ban,etc.Incidence and Clinical Characteristics of Pulmonary Hypertension in Patients with Idiopathic Pulmonary Fibrosis[J].2015,(7).
[3]Harold R, Collard,Eric, Yow,Luca, Richeldi,etc.Suspected acute exacerbation of idiopathic pulmonary fibrosis as an outcome measure in clinical trials.[J].2013,14.
[4]Kim,D.S..Acute Exacerbation of Idiopathic Pulmonary Fibrosis[J].2012,33(1).
[5]du Bois RM,Sahn SA,Bradford WZ,etc.Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials.[J].2011,377(9779).
[6]Hong SB,Song JW,Koh Y,etc.Acute exacerbation of idiopathic pulmonary fibrosis: incidence, risk factors and outcome.[J].2011,37(2).
[7]Ryerson,C.J.,Vittinghoff,E.,Ley,B.,etc.Predicting survival across chronic interstitial lung disease: The ILD-GAP model[J].2014,145(4).
[8]Qiu Meihua,Chen Yuqing,Ye Qiao.Risk?factors for acute exacerbation of idiopathic pulmonary fibrosis: A systematic review and meta‐analysis[J].2018,12(3).
[9]Johannson,K.A.,Vittinghoff,E.,Lee,K.,etc.Acute exacerbation of idiopathic pulmonary fibrosis associated with air pollution exposure[J].2014,43(4).
[10].American Thoracic Society. Idiopathic pulmonary fibrosis: diagnosis and treatment. International consensus statement. American Thoracic Society (ATS), and the European Respiratory Society (ERS).[J].2000,161.
[11]Mura,M.,Porretta,M.A.,Bargagli,E.,etc.Predicting survival in newly diagnosed idiopathic pulmonary fibrosis: A 3-year prospective study[J].2012,40(1).
[12]Toshio Fujimoto,Tsuyoshi Okazaki,Tadashi Matsukura,etc.Operation for lung cancer in patients with idiopathic pulmonary fibrosis: surgical contraindication?[J].2003,76(5).
[13]Collard HR,King TE Jr,Ley B.Clinical course and prediction of survival in idiopathic pulmonary fibrosis.[J].2011,183(4).
[14]Valeyre D,King TE Jr,Bradford WZ,etc.Ascertainment of individual risk of mortality for patients with idiopathic pulmonary fibrosis.[J].2011,184(4).
[15]D S, Kim,J H, Park,B K, Park,etc.Acute exacerbation of idiopathic pulmonary fibrosis: frequency and clinical features.[J].2006,27(1).
[16]Ley, Brett,Bradford, Williamson Z.,Weycker, Derek,etc.Unified baseline and longitudinal mortality prediction in idiopathic pulmonary fibrosis[J].2015,45(5).
[17]Hasegawa,Y.,Kondoh,Y.,Kimura,T.,etc.Acute exacerbation of IPF following diagnostic bronchoalveolar lavage procedures[J].2012,106(3).
[18]Raghu G,Collard HR,Egan JJ,etc.An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management.[J].2011,183(6).
[19]Kawaguchi T,Takahama M,Kushibe K,etc.Operative indications for lung cancer with idiopathic pulmonary fibrosis.[J].2007,55(8).
[20]Sato,T.,Teramukai,S.,Kondo,H.,etc.Impact and predictors of acute exacerbation of interstitial lung diseases after pulmonary resection for lung cancer[J].2014,147(5).
[21].Combined pulmonary fibrosis and emphysema: a retrospective analysis of clinical characteristics, treatment and prognosis[J].2016.
[22]Wells AU,Desai SR,Rubens MB,etc.Idiopathic pulmonary fibrosis: a composite physiologic index derived from disease extent observed by computed tomography.[J].2003,167(7).
[23]Fernando J, Martinez,Sharon, Safrin,Derek, Weycker,etc.The clinical course of patients with idiopathic pulmonary fibrosis.[J].2005,142.
[24]Egan TM,Murray S,Edwards LB,etc.Development of the new lung allocation system in the United States.[J].2006,6(5 Pt.2).
[25]Lederer DJ,Wilt JS,D'Ovidio F,etc.Six-minute-walk distance predicts waiting list survival in idiopathic pulmonary fibrosis.[J].2006,174(6).
[26]Travis,W.D.,Costabel,U.,Hansell,D.M.,etc.An official American Thoracic Society/European Respiratory Society statement: Update of the international multidisciplinary classification of the idiopathic interstitial pneumonias[J].2013,188(6).
[27]King TE Jr,Pardo A,Selman M.Idiopathic pulmonary fibrosis.[J].2011,378(9807).
[28]Ryerson, Christopher J.,O'Connor, Darragh,Dunne, James V.,etc.Predicting Mortality in Systemic Sclerosis-Associated Interstitial Lung Disease Using Risk Prediction Models Derived From Idiopathic Pulmonary Fibrosis[J].2015,148(5).
[29]Bradford WZ,King TE Jr,Albera C.Effect of interferon gamma-1b on survival in patients with idiopathic pulmonary fibrosis (INSPIRE): a multicentre, randomised, placebo-controlled trial.[J].2009,374(9685).
[30]DuBois,R.M.,Albera,C.,Bradford,W.Z.,etc.6-Minute Walk Distance is an Independent Predictor of Mortality in Patients with Idiopathic Pulmonary Fibrosis[J].2014,43(5).
[31]Ley,B.,Ryerson,C.J.,Vittinghoff,E.,etc.A multidimensional index and staging system for idiopathic pulmonary fibrosis[J].2012,156(10).
[32]Ghulam, Saydain,Ashiq, Islam,Bekele, Afessa,etc.Outcome of patients with idiopathic pulmonary fibrosis admitted to the intensive care unit.[J].2002,166(6).
[33]Ohshimo,S.,Ishikawa,N.,Horimasu,Y.,etc.Baseline KL-6 predicts increased risk for acute exacerbation of idiopathic pulmonary fibrosis[J].2014,108(7).
[34]Konishi, Satoshi,Arita, Machiko,Ito, Isao,etc.Composite Physiologic Index, Percent Forced Vital Capacity and Percent Diffusing Capacity for Carbon Monoxide Could Be Predictors of Pirfenidone Tolerability in Patients with Idiopathic Pulmonary Fibrosis[J].2015,54(22).
[35]Tatsumi K,Iyoda A,Fujisawa T,etc.Impact of interstitial lung disease on surgical morbidity and mortality for lung cancer: Analyses of short-term and long-term outcomes.[J].2003,126(4).
[36]Charlotte Hyldgaard,Ole Hilberg,Elisabeth Bendstrup.How does comorbidity influence survival in idiopathic pulmonary fibrosis?[J].2014,108(4).
[37]Fisher, Jolene H.,Al-Hejaili, Faris,Kandel, Sonja,etc.Multi-dimensional scores to predict mortality in patients with idiopathic pulmonary fibrosis undergoing lung transplantation assessment[J].2017,125.
[38]Bradford WZ,Noble PW,Raghu G,etc.A placebo-controlled trial of interferon gamma-1b in patients with idiopathic pulmonary fibrosis.[J].2004,350(2).
[39]Collard, Harold R.,Ryerson, Christopher J.,Corte, Tamera J.,etc.Acute Exacerbation of Idiopathic Pulmonary Fibrosis An International Working Group Report[J].2016,194(3).
[40]Olman MA,Brown KK,Lynch DA,etc.Acute exacerbations of idiopathic pulmonary fibrosis.[J].2007,176(7).